PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Metastatic
Interventions: DRUG: Fluzoparib|DRUG: Dalpiciclib|DRUG: Fulvestrant/AI
Sponsor: Fudan University
Collaborators: Peking University Cancer Hospital & Institute|First Hospital of China Medical University|Sun Yat-sen University|First Affiliated Hospital Xi'an Jiaotong University|Liaoning Tumor Hospital & Institute|Chongqing University Cancer Hospital|Northern Jiangsu People's Hospital|Fujian Medical University Union Hospital|Ningbo Medical Center Lihuili Hospital|Shanghai First Maternity and Infant Hospital|Shanghai 6th People's Hospital|Affiliated Hospital of Nantong University